Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492048 | 0.82 | CYP2C9 (0.48) | ALOX5APFEN1BRAFCYP2C9CYP3A4 | |
| SCHEMBL14964633 | 0.80 | KDM1A (0.42) | ALOX5APFEN1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL413622 | 0.80 | CYP2C9 (0.60) | ACLYALOX5APFEN1BRAFCYP2C9 | |
| SCHEMBL26401647 | 0.80 | CYP2C9 (0.42) | ACLYBRAFCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL25111331 | 0.79 | ACLY (0.41) | ACLYALOX5APFEN1BRAFCYP2C9 | |
| SCHEMBL1437637 | 0.77 | PSIP1 (0.56) | ALOX5APFEN1BRAFCYP2C9CYP3A4 | |
| SCHEMBL1492041 | 0.76 | POLB (0.42) | ALOX5APFEN1BRAFCYP2C9CYP3A4 | |
| SCHEMBL3017382 | 0.75 | CYP2C19 (0.52) | CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL14964586 | 0.75 | CYP3A4 (0.47) | BRAFCYP2C9CYP3A4CYP2C19PTGES2 | |
| SCHEMBL14317780 | 0.74 | ACLY (0.39) | ACLYALOX5APFEN1BRAFCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2647637-B1 | PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | MEDPACTO INC (KR) | 2016-02-03 | — | — | EP | disclosed |
| US-9216981-B2 | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient | MEDPACTO, INC. (KR) | 2015-12-22 | — | — | US | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20130317023-A1 | NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | YOUAI CO., LTD. (KR) | 2013-11-28 | — | — | US | disclosed |
| EP-2647637-A2 | NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | Youai Co., Ltd. (KR) | 2013-10-09 | — | — | EP | disclosed |
| US-20130023531-A1 | PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012085127-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | CDK2, TNNI3K, CDK1 | ACLY 1836/4885ALOX5AP 4844/4885FEN1 4344/4885 |
| US-20130317023-A1 | NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | BRAF, RAF1, ARAF | ACLY 4723/4885ALOX5AP 2439/4885FEN1 3929/4885 |
| US-20130023531-A1 | PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | CDK2, CDK4, CCNI | ACLY 3120/4885ALOX5AP 3735/4885FEN1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.